Introduction/Background Brachytherapy (BT), performed as intracavitary (IC) or interstitial, has an irreplaceable role as a solitary treatment modality (mostly palliative, hemostatic effect) or in combination with external beam radiation (EBRT) in definitive radiotherapy treatment (RT) for cervical and uterine carcinomas. The use of ultrasound (US) guidance during the insertion of the uterine probe/s is of essential importance in achieving the correct position of the applicator system, adequate BT dose distribution, and thus the success of the treatment.

Methodology US-guided BT applications are standard procedure in the brachytherapy daily practice in our Institute. The aim of this study was to present the results of the use of US by the brachytherapy team during regular BT treatments to prevent uterine probe malposition.

Results From 01.01.2023. to 05.05.2023. a total of 292 IC BT applications were conducted in our Brachytherapy Department, in definitive or palliative RT of cervical and uterine cancer. Of these, 242 (82,9%) were 2D radiography planned, while 50 (17,1%) were performed as 3D MRI-based planning, and 287 (98,2%) of them were US-guided applications. The inadequate position of the uterine probe out of the uterine cavity was US verified in 2 patients, and the BT session was canceled. After two weeks of intermission, BT applications were continued. The patients had no symptoms, they were conservatively treated and definitive RT was completed.

Conclusion Based on our own experience, and considering the data from the published papers, a clear recommendation can be made to perform US guidance during all IC BT applications in definitive/palliative RT of cervical and uterine carcinomas.

Disclosures The authors disclose no conflict of interest.